ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARDELYX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.94 (−38.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ARDELYX, INC. grew revenue 16.8% to $450.89M over the twelve months to Jun 30, 2026. Free cash flow was -$17.92M.
Revenue
$450.89M
+16.8% vs. a year earlier
Operating income
-$35.45M
TTM Q2 2026
Free cash flow
-$17.92M
TTM Q2 2026
EPS, diluted
-$0.22
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $766.53M
- P/E ratio
- –
- Price to sales
- 1.70
- Price to book
- 5.14
- Dividend yield
- –
- Free cash flow yield
- -2.34%
Fundamentals
- Revenue
- $450.89M
- Net income
- -$55.70M
- EPS, diluted
- -$0.22
- Free cash flow
- -$17.92M
- Book value per share
- $0.60
- Diluted shares
- 248M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$450.89M+16.8% YoY
Gross profit
$425.49M+29.9% YoY
Operating income
-$35.45M
Net income
-$55.70M
EPS, diluted
-$0.22
Free cash flow
-$17.92M
Reported periodTrailing twelve months